Nuwellis (NUWE) 10-Q 8 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 05, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	CHF Solutions, Inc.
Entity Central Index Key	0001506492
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		2,584,972
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Address, State or Province	MN

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 7,402	$ 5,480
Accounts receivable	932	786
Inventory	1,690	1,658
Other current assets	278	203
Total current assets	10,302	8,127
Property, plant and equipment, net	574	536
Operating lease right-of-use asset	531	0
Other assets	21	113
TOTAL ASSETS	11,428	8,776
Current liabilities
Accounts payable	1,178	1,133
Accrued compensation	1,186	1,498
Current portion of operating lease liability	176	0
Other current liabilities	97	209
Total current liabilities	2,637	2,840
Operating lease liability	357	0
Total liabilities	2,994	2,840
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of June 30, 2019 and December 31, 2018, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 2,328,320 and 513,445, respectively	0	0
Additional paid-in capital	215,761	204,101
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,218	1,223
Accumulated deficit	(208,545)	(199,388)
Total stockholders' equity	8,434	5,936
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	11,428	8,776
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series G Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,418,623	39,969,465
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	2,328,320	513,445
Common stock, shares outstanding (in shares)	2,328,320	513,445
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	535	535
Preferred stock, shares issued (in shares)	535	535
Preferred stock, shares outstanding (in shares)	535	535
Series G Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	550,842	0
Preferred stock, shares issued (in shares)	550,842	0
Preferred stock, shares outstanding (in shares)	550,842	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 1,677	$ 1,099	$ 2,892	$ 2,136
Costs and Expenses:
Cost of goods sold	835	870	1,447	1,771
Selling, general and administrative	3,973	3,765	7,991	7,776
Research and development	1,297	643	2,607	1,122
Total costs and expenses	6,105	5,278	12,045	10,669
Loss from operations	(4,428)	(4,179)	(9,153)	(8,533)
Loss before income taxes	(4,428)	(4,179)	(9,153)	(8,533)
Income tax expense	(2)	(2)	(4)	(2)
Net loss	$ (4,430)	$ (4,181)	$ (9,157)	$ (8,535)
Basic and diluted loss per share (in dollars per share)	$ (1.93)	$ (13.03)	$ (8.82)	$ (28.03)
Weighted average shares outstanding - basic and diluted (in shares)	2,295	321	1,550	304
Other comprehensive loss:
Foreign currency translation adjustments	$ (3)	$ (2)	$ (5)	$ (1)
Total comprehensive loss	$ (4,433)	$ (4,183)	$ (9,162)	$ (8,536)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 0	$ 197,367	$ 1,227	$ (182,356)	$ 16,238
Balance (in shares) at Dec. 31, 2017	271,357
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,354)	(4,354)
Foreign currency translation adjustment	0	0	1	0	1
Stock-based compensation and stock awards, net	$ 0	501	0	0	501
Stock-based compensation and stock awards, net (in shares)	3
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	32,365
Balance at Mar. 31, 2018	$ 0	197,868	1,228	(186,710)	12,386
Balance (in shares) at Mar. 31, 2018	303,725
Balance at Dec. 31, 2017	$ 0	197,367	1,227	(182,356)	16,238
Balance (in shares) at Dec. 31, 2017	271,357
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(8,535)
Foreign currency translation adjustment					(1)
Balance at Jun. 30, 2018	$ 0	198,474	1,226	(190,891)	8,809
Balance (in shares) at Jun. 30, 2018	321,855
Balance at Mar. 31, 2018	$ 0	197,868	1,228	(186,710)	12,386
Balance (in shares) at Mar. 31, 2018	303,725
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,181)	(4,181)
Foreign currency translation adjustment	0	0	(2)	0	(2)
Stock-based compensation and stock awards, net	$ 0	606	0	0	606
Stock-based compensation and stock awards, net (in shares)	3
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	18,127
Balance at Jun. 30, 2018	$ 0	198,474	1,226	(190,891)	8,809
Balance (in shares) at Jun. 30, 2018	321,855
Balance at Dec. 31, 2018	$ 0	204,101	1,223	(199,388)	5,936
Balance (in shares) at Dec. 31, 2018	513,445
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,727)	(4,727)
Foreign currency translation adjustment	0	0	(2)	0	(2)
Stock-based compensation and stock awards, net	$ 0	362	0	0	362
Stock-based compensation and stock awards, net (in shares)	3
Issuance of common and preferred stock, net	$ 0	10,959	0	0	10,959
Issuance of common and preferred stock, net (in shares)	455,178
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	1,100,394
Balance at Mar. 31, 2019	$ 0	215,422	1,221	(204,115)	12,528
Balance (in shares) at Mar. 31, 2019	2,069,020
Balance at Dec. 31, 2018	$ 0	204,101	1,223	(199,388)	5,936
Balance (in shares) at Dec. 31, 2018	513,445
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(9,157)
Foreign currency translation adjustment					(5)
Balance at Jun. 30, 2019	$ 0	215,761	1,218	(208,545)	8,434
Balance (in shares) at Jun. 30, 2019	2,328,320
Balance at Mar. 31, 2019	$ 0	215,422	1,221	(204,115)	12,528
Balance (in shares) at Mar. 31, 2019	2,069,020
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,430)	(4,430)
Foreign currency translation adjustment	0	0	(3)	0	(3)
Stock-based compensation and stock awards, net	$ 0	339	0	0	339
Stock-based compensation and stock awards, net (in shares)	0
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	259,300
Balance at Jun. 30, 2019	$ 0	$ 215,761	$ 1,218	$ (208,545)	$ 8,434
Balance (in shares) at Jun. 30, 2019	2,328,320

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating Activities:
Net loss	$ (9,157)	$ (8,535)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	120	115
Stock-based compensation expense, net	701	1,107
Changes in operating assets and liabilities:
Accounts receivable	(146)	(107)
Inventory	(32)	(727)
Other current assets	(75)	(48)
Other assets and liabilities	(18)	0
Accounts payable and accrued expenses	(267)	(283)
Net cash used in operating activities	(8,874)	(8,478)
Investing activities:
Purchases of property and equipment	(158)	(121)
Net cash used in investing activities	(158)	(121)
Financing activities:
Net proceeds from public stock offering, net	10,959	0
Net cash provided by financing activities	10,959	0
Effect of exchange rate changes on cash	(5)	(1)
Net increase (decrease) in cash and cash equivalents	1,922	(8,600)
Cash and cash equivalents - beginning of period	5,480	15,595
Cash and cash equivalents - end of period	$ 7,402	$ 6,995

Nature of Business and Basis of

Nature of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Nature of Business and Basis of Presentation [Abstract]
Nature of Business and Basis of Presentation	Note 1 – Nature of Business and Basis of Presentation Nature of Business : Previously, the Company was focused on developing the C-Pulse® Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. In August 2016, the Company acquired the business associated with the Aquadex FlexFlow system (herein referred to as the “Aquadex Business”) from a subsidiary of Baxter International, Inc. (“Baxter”), and refocused its strategy to fully devote its resources to the Aquadex Business. In December 2018, the Company’s stockholders approved a reverse split of its outstanding common stock at a ratio in the range of 1-for-2 to 1-for 14 and, in January 2019, the board of directors approved a 1-for-14 reverse split of the Company’s outstanding common stock that became effective after trading on January 2, 2019. This reverse stock split did not change the par value of the Company’s common stock or the number of common or preferred shares authorized by the Company’s Fourth Amended and Restated Certificate of Incorporation. All share and per-share amounts have been retroactively adjusted to reflect the reverse stock split for all periods presented. Principles of Consolidation: For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Going Concern: The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex FlexFlow. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing and distributing the Aquadex FlexFlow and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability. On April 24, 2017, November 27, 2017, July 3, 2018, and March 12, 2019, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $39.8 million after deducting the underwriting discounts and commissions and other costs associated with the offerings (see Note 4 –Equity). The Company will require additional funding to grow its Aquadex Business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions. Should warrant exercises not materialize or future capital raising be unsuccessful, the Company may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern. Revenue Recognition: Revenue from Contracts with Customers Accounts Receivable Inventories ( in thousands) June 30, 2019 December 31, 2018 Finished Goods $ 465 $ 517 Work in Process 96 34 Raw Materials 1,129 1,107 Total $ 1,690 $ 1,658 Contingent consideration Loss per share: Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: June 30 2019 2018 Warrants to purchase common stock 5,430,721 608,787 Series G convertible preferred stock 550,842 - Series F convertible preferred stock 102,185 20,740 Stock options 241,635 152,142 Restricted stock units - 9 Total 6,325,383 781,678 The following table reconciles reported net loss with reported net loss per share for the periods ended June 30, 2019: (in thousands, except per share amounts) Three months Six months Net loss $ (4,430 ) $ (9,157 ) Deemed dividend to preferred shareholders (see Note 4) (4,509 ) Net loss after deemed dividend (4,430 ) (13,666 ) Weighted average shares outstanding 2,295 1,550 Basic and diluted loss per share $ (1.93 ) $ (8.82 ) New Accounting Pronouncements: In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement – Disclosure Framework (Topic 820). The updated guidance improves and simplifies the disclosure requirements on fair value measurements for level 3 assets and liabilities valued at fair value. The Company early-adopted the guidance effective for this reporting period and the effect on the consolidated financial statements was not material.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2019
Revenue Recognition [Abstract]
Revenue Recognition	Note 2 – Revenue Recognition Net Sales The Company sells its products in the United States primarily through a direct sales force. Customers who purchase the Company’s products include hospitals and clinics throughout the United States. In countries outside the United States, the Company sells its products through a limited number of specialty healthcare distributors in the United Kingdom, Italy, Spain, Germany, Southeast Asia, Brazil and India. These distributors resell the Company’s products to hospitals and clinics in their respective geographies. Revenue from product sales are recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company’s standard shipping terms are FOB shipping point, unless the customer requests that control and title to the inventory transfer upon delivery. Revenue includes shipment and handling fees charged to customers. Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. The majority of our contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers which are recognized over time. This revenue represents less than 1% of net sales for the three and six months ended June 30, 2019 and 2018. The unfulfilled performance obligations related to these extended service plans is included in deferred revenue, which is included in other current liabilities on the condensed consolidated balance sheet. The majority of the deferred revenue is expected to be recognized within one year. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold. Product Returns: believes that future returns of its products will be minimal.

Debt

Debt	6 Months Ended
	Jun. 30, 2019
Debt [Abstract]
Debt	Note 3 - Debt On August 5, 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (the Bank). Under this agreement, the Bank agreed to provide the Company with up to $5.0 million in debt financing, consisting of a term loan in an aggregate original principal amount not to exceed $4.0 million (the “Term Loan”) and a revolving line of credit in an aggregate principal amount not to exceed $1.0 million outstanding at any time (the “Revolving Line”). Proceeds from the loans were to be used for general corporate and working capital purposes. Advances under the Term Loan were available to the Company until November 30, 2016 and were subject to the Company’s compliance with liquidity covenants. The Term Loan expired unused on November 30, 2016 and the Term Loan is no longer available to be drawn. Advances under the Revolving Line are available to the Company until March 31, 2020 and accrue interest at a floating annual rate equal to 1.75% or 1.0% above the prime rate, depending on liquidity factors. Outstanding borrowings, if any, are collateralized by all of the Company’s assets, excluding intellectual property which is subject to a negative pledge. There were no borrowings outstanding under this facility as of June 30, 2019 or December 31, 2018.

Equity

Equity	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Equity	Note 4 - Equity Series F Convertible Preferred Stock The offering was comprised of Series F convertible preferred stock, convertible into shares of the Company’s common stock at an initial conversion price of $63.00 per share. Each share of Series F preferred stock was accompanied by a Series 1 warrant, which was to expire on the first anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $63.00 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $63.00 per share. The Series F preferred stock and the warrants were immediately separable and were issued separately. The conversion price of the Series F preferred stock will be adjusted in the event of a stock split, combination, reclassification or stock dividend or if the Company consummates a fundamental transaction. The Series F preferred stock also has full ratchet price based anti-dilution protection, subject to customary carve outs, in the event of a down-round financing at a price per share below the conversion price of the Series F preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company’s common stock exceeds 300% of the then-effective conversion price of the Series F preferred stock and the daily dollar trading volume for each trading day during such period exceeds $200,000). The exercise price of the warrants is fixed and does not contain any variable pricing features, nor any price based anti-dilutive features, apart from customary adjustments for stock splits, combinations, reclassifications, stock dividends or fundamental transactions. A total of 18,000 shares of Series F Convertible Preferred Stock initially convertible into 286,714 shares of common stock and warrants to purchase 573,310 shares of common stock were issued in the offering. As noted below, effective July 3, 2018, the conversion price of the Series F convertible preferred stock was reduced from $63.00 to $29.68, the per share price in the July 2018 Offering described below. Effective March 12, 2019, the conversion price of the Series F convertible preferred stock was reduced again from $29.68 to $5.25, the per share price to the public of the Series G convertible preferred stock which closed in an underwritten public offering on March 12, 2019, and each share of the remaining Series F convertible preferred stock is convertible into 191 shares of the Company’s common stock. As of both June 30, 2019, and December 31, 2018, 535 shares of the Series F convertible preferred stock remained outstanding. July 2018 Offering: On July 3, 2018, the Company closed on an underwritten public offering of 181,941 shares of its common stock at a public offering price of $29.68 per share, for gross proceeds of $5.4 million, including the full exercise of the underwriters’ over-allotment option to purchase additional shares of the Company’s common stock (the “July 2018 Offering”). deducting underwriting discounts and commissions and offering expenses. In connection with the July 2018 Offering, and to induce certain institutional investors who hold warrants issued by the Company in November 2017 (“November 2017 Warrants”) to participate in the July 2018 Offering, the Company entered into letter agreements with such institutional investors. Pursuant to the terms of these agreements, the Company agreed, effective July 3, 2018, to reduce the per share exercise price of the November 2017 Warrants held by such institutional investors to $29.68 and to extend the expiration date of the warrants that were to expire on November 27, 2018 to November 27, 2019. The number of common shares underlying the warrants that were repriced did not change. The repriced warrants are exercisable for 554,322 shares of common stock in the aggregate, of which, following such amendment, half expire on November 27, 2019 and half expire on November 27, 2024. The repricing of the warrants was accounted as an equity financing cost, with no impact to net proceeds from the offering. As noted above, the Company’s outstanding Series F preferred stock is subject to full-ratchet anti-dilution protection in the event the Company sells any common stock at a price lower than the then-conversion price of the Series F preferred stock. As a result of the July 2018 Offering, effective July 3, 2018, the conversion price of the Series F preferred stock was reduced from $63.00 to $29.68, the per share price in the July 2018 Offering. Series G Convertible Preferred Stock and March 2019 Offering The March 2019 Offering was comprised of 455,178 shares of common stock priced at $5.25 per share and 1,910,536 shares of Series G convertible preferred stock, convertible into common stock at $5.25 per share. Each share of Series G convertible preferred stock and each share of common stock was accompanied by a Series 1 warrant and a Series 2 warrant. The Series 1 warrants are exercisable into 2,365,714 shares of common stock and the Series 2 warrants are exercisable into 2,365,714 shares of common stock. Series 1 warrants expire on the fifth anniversary of the date of issuance and are exercisable at $5.25 to purchase one share of common stock. Series 2 warrants expire on the earlier of: (i) the eighteen-month anniversary of the date of issuance and (ii) the 30th trading day following the public announcement of the receipt from the U.S. Food and Drug Administration of clearance or approval of a modification to the product label for the Aquadex FlexFlow system to include pediatric patients. Series 2 warrants are exercisable at $5.25 per share of common stock. As of June 30, 2019, 1,359,694 shares of the Series G convertible preferred stock had been converted into common stock and 550,842 remained outstanding. As noted above, the Company’s outstanding Series F convertible preferred stock is subject to full-ratchet anti-dilution protection in the event the Company sells any common stock at a price lower than the then-conversion price of the Series F convertible preferred stock. As a result of the March 2019 Offering, the conversion price of the Series F convertible preferred stock was reduced from $29.68, to $5.25, the per share price of the Series G convertible preferred stock. Placement Agent Fees Market-Based Warrants

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2019
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 5 - Stock-Based Compensation Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The following table presents the classification of stock-based compensation expense recognized for the periods below: Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Selling, general and administrative expense $ 309 $ 555 $ 635 $ 1,006 Research and development expense 30 51 66 101 Total stock-based compensation expense $ 339 $ 606 $ 701 $ 1,107

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2019
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	Note 6 - Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, warrants, and contingent consideration. Pursuant to the requirements of ASC Topic 820 “Fair Value Measurement,” • Level 1 • Level 2 • Level 3 The fair value of the Company’s contingent consideration, as described in Note 1, was initially measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value, and it was considered a Level 3 instrument. The discount rate used was determined at the time of measurement in accordance with accepted valuation methods. The Company measured the liability on a recurring basis using Level 3 inputs including probabilities of payment and projected payment dates. As of June 30, 2019, the Company deemed the likelihood of payment of the additional consideration to be remote and estimated the fair value of the contingent consideration to be $0. Therefore, the Company reduced this liability to $0 as of June 30, 2019. The following is a rollforward of the fair value of Level 3 items: (in thousands) Balance December 31, 2018 $ 126 Change in fair value (126 ) Balance as of June 30, 2019 $ - The fair value of the market-based warrants described in Note 4 was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. These warrants are classified as permanent equity and as a result, were measured at the grant date and are not required to be remeasured to fair value at each reporting period end. All cash equivalents are considered Level 1 measurements for all periods presented. The Company does not have any financial instruments classified as Level 2 or any other classified as Level 3 and there were no movements between these categories during the periods ended June 30, 2019 and December 31, 2018. The Company believes that the carrying amounts of all remaining financial instruments approximate their fair value due to their relatively short maturities.

Operating Leases

Operating Leases	6 Months Ended
	Jun. 30, 2019
Operating Leases [Abstract]
Operating Leases	Note 7 – Operating Leases The Company leases office and manufacturing space under a non-cancelable operating lease that expires in March 2022. In August 2018, the Company entered into a third amendment to the lease, extending the term of the lease from March 31, 2019 to March 31, 2022. Beginning on April 1, 2019, the annual base rent is $9.00 per square foot, subject to annual increases of $0.25 per square foot. The cost components of the Company’s operating lease were as follows for the three and six months ended June 30, 2019: (in thousands) Three Months Six Months Operating lease cost $ 53 $ 102 Variable lease cost 33 59 Total $ 86 $ 161 Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased office and manufacturing space. Maturities of our lease liability for our operating lease are as follows as of June 30, 2019: (in thousands) 2019 $ 104 2020 213 2021 219 2022 55 Total lease payments 591 Less: Interest (58 ) Present value of lease liability $ 533 As of June 30, 2019, the remaining lease term was 2.75 years and discount rate was 7.5%. For the six months ended June 30, 2019, the operating cash outflows from our operating lease for office and manufacturing space were $102,000. Rent expense related to operating leases for office and manufacturing space and office equipment was approximately $54,000 and $106,000 for the three and six months ended June 30, 2018, respectively. Future minimum lease payments, under non-cancelable operating leases as of December 31, 2018, were approximately $217,000, $220,000, $219,000, $55,000, and $0 for each of the years ended December 31, 2019, through 2023, respectively.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Taxes [Abstract]
Income Taxes	Note 8 – Income Taxes The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying condensed consolidated financial statements. As of June 30, 2019, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2018.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 9—Commitments and Contingencies Employee Retirement Plan: Contingent Consideration: In addition, it also agreed that if shares of its common stock cease to be publicly traded on the Nasdaq Capital Market, Baxter has the option to require the Company to repurchase, in cash, all or any part of the common shares held by Baxter at a price equal to their fair market value, as determined by a third-party appraiser.

Nature of Business and Basis _2

Nature of Business and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2019
Nature of Business and Basis of Presentation [Abstract]
Principles of Consolidation	Principles of Consolidation: For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Going Concern	Going Concern: The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex FlexFlow. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing and distributing the Aquadex FlexFlow and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability. On April 24, 2017, November 27, 2017, July 3, 2018, and March 12, 2019, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $39.8 million after deducting the underwriting discounts and commissions and other costs associated with the offerings (see Note 4 –Equity). The Company will require additional funding to grow its Aquadex Business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions. Should warrant exercises not materialize or future capital raising be unsuccessful, the Company may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.
Revenue Recognition	Revenue Recognition: Revenue from Contracts with Customers
Accounts Receivable	Accounts Receivable
Inventories	Inventories ( in thousands) June 30, 2019 December 31, 2018 Finished Goods $ 465 $ 517 Work in Process 96 34 Raw Materials 1,129 1,107 Total $ 1,690 $ 1,658
Contingent Consideration	Contingent consideration
Loss per Share	Loss per share: Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: June 30 2019 2018 Warrants to purchase common stock 5,430,721 608,787 Series G convertible preferred stock 550,842 - Series F convertible preferred stock 102,185 20,740 Stock options 241,635 152,142 Restricted stock units - 9 Total 6,325,383 781,678 The following table reconciles reported net loss with reported net loss per share for the periods ended June 30, 2019: (in thousands, except per share amounts) Three months Six months Net loss $ (4,430 ) $ (9,157 ) Deemed dividend to preferred shareholders (see Note 4) (4,509 ) Net loss after deemed dividend (4,430 ) (13,666 ) Weighted average shares outstanding 2,295 1,550 Basic and diluted loss per share $ (1.93 ) $ (8.82 )
New Accounting Pronouncements	New Accounting Pronouncements: In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard which allowed it to carry forward the historical lease classification. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement – Disclosure Framework (Topic 820). The updated guidance improves and simplifies the disclosure requirements on fair value measurements for level 3 assets and liabilities valued at fair value. The Company early-adopted the guidance effective for this reporting period and the effect on the consolidated financial statements was not material.

Nature of Business and Basis _3

Nature of Business and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2019
Nature of Business and Basis of Presentation [Abstract]
Inventories	Inventories consisted of the following: ( in thousands) June 30, 2019 December 31, 2018 Finished Goods $ 465 $ 517 Work in Process 96 34 Raw Materials 1,129 1,107 Total $ 1,690 $ 1,658
Potential Shares of Common Stock not Included in Diluted Net Loss Per Share	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: June 30 2019 2018 Warrants to purchase common stock 5,430,721 608,787 Series G convertible preferred stock 550,842 - Series F convertible preferred stock 102,185 20,740 Stock options 241,635 152,142 Restricted stock units - 9 Total 6,325,383 781,678
Reconciliation of Reported Net Loss with Reported Net Loss Per Share	The following table reconciles reported net loss with reported net loss per share for the periods ended June 30, 2019: (in thousands, except per share amounts) Three months Six months Net loss $ (4,430 ) $ (9,157 ) Deemed dividend to preferred shareholders (see Note 4) (4,509 ) Net loss after deemed dividend (4,430 ) (13,666 ) Weighted average shares outstanding 2,295 1,550 Basic and diluted loss per share $ (1.93 ) $ (8.82 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Stock-Based Compensation [Abstract]
Classification of Stock-Based Compensation Expense	The following table presents the classification of stock-based compensation expense recognized for the periods below: Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Selling, general and administrative expense $ 309 $ 555 $ 635 $ 1,006 Research and development expense 30 51 66 101 Total stock-based compensation expense $ 339 $ 606 $ 701 $ 1,107

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value of Financial Instruments [Abstract]
Fair Value of Level 3 Warants	The following is a rollforward of the fair value of Level 3 items: (in thousands) Balance December 31, 2018 $ 126 Change in fair value (126 ) Balance as of June 30, 2019 $ -

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Operating Leases [Abstract]
Cost Components of Operating Leases	The cost components of the Company’s operating lease were as follows for the three and six months ended June 30, 2019: (in thousands) Three Months Six Months Operating lease cost $ 53 $ 102 Variable lease cost 33 59 Total $ 86 $ 161
Maturities of Lease Liability	Maturities of our lease liability for our operating lease are as follows as of June 30, 2019: (in thousands) 2019 $ 104 2020 213 2021 219 2022 55 Total lease payments 591 Less: Interest (58 ) Present value of lease liability $ 533

Nature of Business and Basis _4

Nature of Business and Basis of Presentation, Nature of Business, Going Concern, Accounts Receivable and Inventories (Details) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended	23 Months Ended
	Jan. 31, 2019	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018	Jun. 30, 2019USD ($)	Jun. 30, 2018	Dec. 31, 2018USD ($)	Mar. 12, 2019USD ($)	Aug. 31, 2016USD ($)
Nature of Business [Abstract]
Reverse stock split ratio	0.0714
Going Concern [Abstract]
Accumulated deficit		$ (199,388)	$ (208,545)		$ (208,545)		$ (199,388)
Net proceeds from issuance of convertible preferred stock								$ 39,800
Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date					30 days
Allowance for doubtful accounts		0	0		$ 0		0
Inventories [Abstract]
Finished Goods		517	465		465		517
Work in Process		34	96		96		34
Raw Materials		1,107	1,129		1,129		1,107
Total		$ 1,658	1,690		1,690		$ 1,658
Contingent Consideration [Abstract]
Fair value of contingent consideration			0		0
Contingent consideration			$ 0		$ 0
Customer One [Member] | Accounts Receivable [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage					23.00%		18.00%
Customer Two [Member] | Accounts Receivable [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage							13.00%
Customer Three [Member] | Accounts Receivable [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage							13.00%
Minimum [Member]
Nature of Business [Abstract]
Reverse stock split ratio		0.5000
Maximum [Member]
Nature of Business [Abstract]
Reverse stock split ratio		0.0714
Aquadex Product Line [Member]
Contingent Consideration [Abstract]
Contingent consideration									$ 126
ASC 606 [Member] | Customer One [Member] | Net Sales [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage			20.00%	17.00%	12.00%	11.00%
ASC 606 [Member] | Customer Two [Member] | Net Sales [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage						11.00%

Nature of Business and Basis _5

Nature of Business and Basis of Presentation, Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					6,325,383	781,678
Reported net loss with reported net loss per share [Abstract]
Net loss	$ (4,430)	$ (4,727)	$ (4,181)	$ (4,354)	$ (9,157)	$ (8,535)
Deemed dividend to preferred shareholders (see Note 4)					(4,509)
Net loss after deemed dividend	$ (4,430)				$ (13,666)
Weighted average shares outstanding (in shares)	2,295,000		321,000		1,550,000	304,000
Basic and diluted loss per share (in dollars per share)	$ (1.93)		$ (13.03)		$ (8.82)	$ (28.03)
New Accounting Pronouncement [Abstract]
Operating lease right-of-use asset	$ 531				$ 531		$ 0
Operating lease liability	$ 533				$ 533
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					5,430,721	608,787
Series G Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					550,842	0
Series F Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					102,185	20,740
Stock Options [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					241,635	152,142
Restricted Stock Units [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)					0	9
ASU 2016-02 [Member] | Adjustments Due to Adoption of ASU 2016-02 [Member]
New Accounting Pronouncement [Abstract]
Operating lease right-of-use asset							600
Operating lease liability							$ 600

Revenue Recognition (Details)

Revenue Recognition (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]
Expected timing of satisfaction, period	1 year		1 year
Sales Revenue [Member] | ASC 606 [Member] | Maximum [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales	1.00%	1.00%	1.00%	1.00%

Debt (Details)

Debt (Details) - Silicon Valley Bank [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Aug. 05, 2016
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 5,000
Term Loan [Member]
Line of Credit Facility [Abstract]
Maximum borrowing capacity			$ 4,000
Maturity date	Nov. 30, 2016
Revolving Line [Member]
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 1,000
Maturity date	Mar. 31, 2020
Total borrowings outstanding	$ 0	$ 0
Revolving Line [Member] | Floating Annual Rate [Member]
Line of Credit Facility [Abstract]
Interest rate	1.75%
Revolving Line [Member] | Prime Rate [Member]
Line of Credit Facility [Abstract]
Interest rate	1.00%

Equity (Details)

Equity (Details) $ / shares in Units, $ in Thousands	Mar. 12, 2019USD ($)$ / sharesshares	Jul. 03, 2018USD ($)$ / sharesshares	Nov. 27, 2017USD ($)$ / sharesshares	Jun. 30, 2019$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Mar. 12, 2019USD ($)$ / sharesshares	May 30, 2019$ / sharesshares	Dec. 31, 2018shares
Class of Stock Disclosures [Abstract]
Net proceeds from issuance of convertible preferred stock | $						$ 39,800
Preferred stock, shares outstanding (in shares)				0	0			0
Expected Stock Price Volatility [Member]
Class of Stock Disclosures [Abstract]
Warrants measurement input				1.3621	1.3621
July 2018 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares)		181,941
Public offering price (in dollars per share) | $ / shares		$ 29.68
Gross proceeds from public stock offering | $		$ 5,400
Net proceeds from public stock offering | $		$ 4,600
Number of shares issuable on the exercise of warrants (in shares)				554,322	554,322
March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares)	455,178
Public offering price (in dollars per share) | $ / shares	$ 5.25					$ 5.25
Warrants [Member] | Consultant [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)							100,000
Exercise price of warrants (in dollars per share) | $ / shares				$ 1.93	$ 1.93		$ 3.18
Series F Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock | $			$ 18,000
Net proceeds from issuance of convertible preferred stock | $			$ 16,200
Conversion price (in dollars per share) | $ / shares	$ 5.25	$ 29.68	$ 63			$ 5.25
Number of consecutive trading days considered for expiration				20 days
Number of consecutive trading days				30 days
Preferred stock issued (in shares)			18,000	535	535			535
Number of shares issuable on conversion of preferred stock (in shares)	191		286,714			191
Preferred stock, shares outstanding (in shares)				535	535			535
Aggregate cash placement fee	8.00%	9.00%
Series F Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock Disclosures [Abstract]
Percentage of volume weighted average price of common stock			300.00%
Trading volume for each trading day | $			$ 200
Series F Convertible Preferred Stock [Member] | Warrants [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)			573,310
Warrants issued to the placement agent (in shares)					0
Series F Convertible Preferred Stock [Member] | Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)			16
Exercise price of warrants (in dollars per share) | $ / shares		$ 29.68	$ 63
Series F Convertible Preferred Stock [Member] | Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)			16
Exercise price of warrants (in dollars per share) | $ / shares		$ 29.68	$ 63
Series G Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock | $	$ 12,400
Net proceeds from issuance of convertible preferred stock | $	$ 11,000
Conversion price (in dollars per share) | $ / shares	$ 5.25					$ 5.25
Number of consecutive trading days				30 days
Preferred stock issued (in shares)				550,842	550,842			0
Preferred stock, shares outstanding (in shares)				550,842	550,842			0
Beneficial conversion amount | $					$ 4,500
Beneficial ownership limitation	4.99%
Conversion of preferred stock into common stock (in shares)				1,359,694
Series G Convertible Preferred Stock [Member] | March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Number of shares issuable on conversion of preferred stock (in shares)	1,910,536					1,910,536
Series G Convertible Preferred Stock [Member] | Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) | $ / shares	$ 5.25					$ 5.25
Number of shares issuable on the exercise of warrants (in shares)	2,365,714					2,365,714
Series G Convertible Preferred Stock [Member] | Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) | $ / shares	$ 5.25					$ 5.25
Number of shares issuable on the exercise of warrants (in shares)	2,365,714					2,365,714

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 339	$ 606	$ 701	$ 1,107
Selling, General and Administrative Expense [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	309	555	635	1,006
Research and Development Expense [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 30	$ 51	$ 66	$ 101

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Fair Value of Financial Instruments [Abstract]
Fair value of contingent consideration	$ 0
Contingent consideration	0
Fair Value Transfers between levels [Abstract]
Level 1 to Level 2 asset transfers	0	$ 0
Level 2 to Level 1 asset transfers	0	0
Level 1 to Level 2 liability transfers	0	0
Level 2 to Level 1 liability transfers	0	$ 0
Level 3 [Member]
Fair value of Level 3 warrants [Roll Forward]
Beginning balance	126
Change in fair value	(126)
Ending balance	$ 0

Operating Leases (Details)

Operating Leases (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)$ / ft²	Jun. 30, 2018USD ($)
Operating Leases [Abstract]
Annual base rent (per square foot) | $ / ft²			9
Annual increase per square foot (in dollars per square foot) | $ / ft²			0.25
Cost Components of Operating Leases [Abstract]
Operating lease cost	$ 53		$ 102
Variable lease cost	33		59
Total	86		161
Maturities of Lease Liability [Abstract]
2019	104		104
2020	213		213
2021	219		219
2022	55		55
Total lease payments	591		591
Less: Interest	(58)		(58)
Present value of lease liability	$ 533		$ 533
Remaining lease term			2 years 9 months
Discount rate	7.50%		7.50%
Operating cash outflows from operating lease			$ 102
Rent expense		$ 54		$ 106
Future Minimum Lease Payments [Abstract]
2019	$ 217		217
2020	220		220
2021	219		219
2022	55		55
2023	$ 0		$ 0

Commitments and Contingencies -

Commitments and Contingencies - (Details) - Aquadex Product Line [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Contingent Consideration [Abstract]
Sale or disposal of business assets threshold for contingent consideration	$ 4,000
Percentage of contingent consideration payments on disposal of business assets	40.00%
Maximum [Member]
Contingent Consideration [Abstract]
Contingent consideration period	3 years